Eighth Replenishment Outcome
At the 54th Board Meeting (February 12–13 in Geneva), the Global Fund reached the following key milestones:
- Funding Outcome: Secured US$12.64 billion for the Eighth Replenishment, demonstrating strong partner support despite global economic volatility.
- Resource Allocation: The Board approved US$10.78 billion for country grants (2027–2029) and US$260 million for catalytic investments.
- Catalytic Focus: An additional US$306 million from the private sector was earmarked to accelerate market shaping, expand access to innovative health products, and strengthen regional manufacturing.
- Ongoing Gap: While hailing the broad engagement of civil society and co-hosts (South Africa and the UK), the Board noted that funding gaps remain and resource mobilization must continue to stay on track to end the three diseases.
Innovation and Transformation through Strategic Shifts
Given the resource-constrained environment and significant changes in global health financing, the Board agreed that funding for the next grant cycle will be allocated in accordance with the following key strategic shifts :
- Achieve greater prioritization of the least-resourced and highest-burden countries.
- Define predictable transition timelines tailored to national contexts, disease burden and economic conditions.
- Optimize the use of all available resources through rigorous programmatic prioritization, increased co-financing, market shaping, reinforced integration into national health systems, and community systems financing.
The Board Strategic Priorities for 2026 and Beyond
The Board has outlined a vision to maximize the impact of every dollar by accelerating equitable access to biomedical breakthroughs. Key priorities include:
- HIV: Scaling up lenacapavir as a primary prevention tool.
- Tuberculosis: Rolling out innovative near-point-of-care molecular diagnostics.
- Malaria: Fast-tracking access to alternative first-line treatments and new vector control tools, such as spatial emanators.
Evolving the Global Health Ecosystem
The Global Fund is committed to a proactive transformation, leveraging its unique model—specifically its strengths in market shaping, pooled procurement, and community-led interventions. The goal is to foster a global health ecosystem that is:
- Collaborative and Coherent: Working seamlessly with international partners.
- Responsive: Prioritizing the specific needs of local countries and communities.
Focus for the LAC Region
As the Eighth Replenishment enters a phase defined by Compartird responsibility and innovation, the Latin America and the Caribbean (LAC) Constituency Leadership is sharpening its focus. The leadership aims to enhance its influence and engagement to ensure the region remains at the forefront of these global strategic shifts.
Global Fund Launched the process to select the New Executive Director
On February 4, the Board launched the search for its next Executive Director, with the appointment scheduled for October 2026 and a four-year term beginning in 2027.
Board leadership selection process update
The Board Leadership selection process was launched on 10th December 2025 and will conclude with the selection of a Board Chair and Vice-Chair who will serve a three-year term beginning in October 2026. Mr. Dereck Springer, Alternate Board Member, was selected to serve as a member of the Board Leadership Nomination Committee (BLNC).
LAC Delegation’s priorities and engagement:
The LAC Delegation is refining its strategic priorities to protect health gains in the face of lower-than-expected funding for the Eighth Replenishment.
Strategic Priorities
- Resource Optimization: Maximizing impact despite budget constraints to protect progress against HIV, TB, and malaria.
- Equity Advocacy: Ensuring budget cuts do not disproportionately affect the LAC region or marginalized populations. Biomedical Innovation: Establishing a regional alliance to secure affordable, generic lenacapavir by 2027.
Diplomatic & Regional Engagement
- High-Level Advocacy: Coordinating with LAC Diplomatic Missions in Geneva, including a 2026 in-person meeting.
- Strategic Convening: Utilizing the LAC Steering Committee to align the Global Fund Secretariat, regional partners, and beneficiary countries ahead of Board meetings.
Strengthened Leadership & Representation
- Dr. Massimo Ghidinelli: Serving a second term on the Strategy Committee (2025–2028); representing LAC interests at Board level in the meetings and retreats scheduled for 2026.
- Mr. Dereck Springer: Selected for the Board Leadership Nomination Committee, overseeing the selection of the new Board Chair and Vice-Chair for the 2026 – 2029 term.
COUNTRY AND REGIONAL COORDINATING MECHANISMS AND OTHER PARTNERS ARE INVITED TO:
- Engage with national governments and partners to develop robust strategies and plans that are essential to protect the gains and sustain the response to the three diseases, while working proactively on transition planning.
- Engage in the early stages of establishing regional partnership alliance to drive innovation and equitable access, ensuring a more efficient use of limited resources, for achieving regional inclusiveness for Lenacapavir access.